The Day the War on Weed Cracked: Inside the DOJ’s Historic Rescheduling Order
On April 23, Acting AG Todd Blanche invoked a 1961 treaty exception to move state-licensed medical cannabis to Schedule III overnight — and opened an expedited Phase Two hearing on adult-use. Here’s how he did it, why SAM and Bill Barr are suing, and the three scenarios that decide what happens next.
For fifty-six years, the federal government told the American people that cannabis had no accepted medical use — a position contradicted by forty states, thousands of physicians, and millions of patients who knew better. On April 23, 2026, Acting Attorney General Todd Blanche signed an order that ended that fiction for good.
The Department of Justice immediately moved FDA-approved cannabis products and all marijuana sold under state-issued medical licenses from Schedule I to Schedule III of the Controlled Substances Act. In the same breath, the DOJ announced an expedited administrative hearing beginning June 29 to consider reclassifying all cannabis — including adult-use — to Schedule III. That hearing must conclude by July 15.
It is the single most consequential federal action on cannabis in the history of the Controlled Substances Act. It is also, by design, far more surgical than the sweeping reform the industry expected. Understanding why the DOJ chose a scalpel over a sledgehammer is the key to understanding what happens next.
What They Did — And the Legal Shortcut That Made It Possible
The order's most remarkable feature is the legal mechanism behind it. Blanche did not follow the standard rescheduling pathway under Section 811(a) and (b) of the CSA, which requires a binding scientific evaluation from the Department of Health and Human Services, notice-and-comment rulemaking, and potentially years of administrative proceedings. That process, launched under Biden in May 2024, had been frozen since early January when litigation and procedural disputes stalled the DEA's administrative hearings.
Instead, Blanche invoked Section 811(d)(1) — the treaty exception. Under this provision, the Attorney General can reschedule a substance without the findings, procedures, or public comment requirements that normally govern CSA scheduling decisions, provided the action is necessary to carry out U.S. obligations under international treaties in effect as of October 27, 1970. The relevant treaty here is the 1961 Single Convention on Narcotic Drugs, which requires signatory nations to limit cannabis to medical and scientific purposes through a regime of prescriptions, licensed manufacturers, production quotas, and import-export controls.
This is not a novel mechanism. The DEA used the same Section 811(d)(1) authority in 2018 to place Epidiolex, the FDA-approved CBD drug, into Schedule V. But using it to reschedule an entire category of state-licensed medical cannabis operations is unprecedented in both scope and ambition. Blanche acknowledged as much in the order itself, noting that while the 2023 HHS recommendation supporting Schedule III placement was not legally required under the treaty pathway, he chose to align with it as a matter of discretion.
The genius — and the vulnerability — of this approach is the same thing: speed. By sidestepping notice-and-comment, DOJ delivered immediate rescheduling for medical cannabis operators on the very day the order was signed. But this same shortcut is what opponents will attack in court. Sheppard Mullin, in its analysis of the order published the same day, noted that while the AG's authority to reschedule under 811(d)(1) rests on a clear statutory foundation, "the authority to amend detailed operational and registration regulations under that same provision is more novel and may attract legal challenge."
The DOJ anticipated exactly this. The order includes an express severability clause, stating that if any provision is declared invalid or stayed by a court, the remaining provisions survive. This is not boilerplate. It is a deliberate structural decision: the DOJ built the order to absorb legal hits without collapsing.
The Two-Phase Strategy
What the industry expected was a single, sweeping reclassification of all cannabis to Schedule III. What it got instead was a carefully bifurcated strategy.
Phase One (effective immediately): FDA-approved cannabis products and marijuana sold under qualifying state medical marijuana licenses are now Schedule III. This covers the 40 states with active medical cannabis programs and any FDA-approved cannabinoid product, though the latter category remains vanishingly small in practice.
Phase Two (beginning June 29): A new, expedited administrative hearing to consider the broader rescheduling of all cannabis from Schedule I to Schedule III. The DOJ simultaneously withdrew the prior Biden-era hearing process, terminating those stalled proceedings entirely and restarting on a compressed timeline. The hearing must conclude no later than July 15 — a two-and-a-half-week window for what would normally take months.
The bifurcation is strategic on multiple levels. First, it delivers immediate, tangible relief to the segment of the industry most defensible politically — medical operators serving patients under state regulatory frameworks. Second, it anchors the Phase One rescheduling in the Single Convention's explicit medical-and-scientific-purposes framework, making it harder to challenge on treaty-compliance grounds. Third, it preserves the question of adult-use rescheduling for a separate proceeding with its own evidentiary record — insulating Phase One from the more politically contentious recreational debate.
As Foley Hoag's analysis put it, the order "goes further than many expected" by creating "a functioning federal framework for state-licensed medical marijuana operators, grounded in cooperative federalism and international treaty compliance."
"They're Slow-Walking Me": How a Rogan Visit Broke the Logjam
The backstory of how this order came to be is as much about political theater as legal strategy.
President Trump signed Executive Order 14177, "Increasing Medical Marijuana and Cannabidiol Research," on December 18, 2025. It directed the Attorney General to take all necessary steps to complete rescheduling in the most expeditious manner possible. Four months of silence followed. DOJ offered "no comment or updates" on the topic through January and February. The Biden-era hearing process remained frozen. Republican opposition — 22 senators led by Ted Budd, including Conference Chair Tom Cotton and Mitch McConnell, plus 26 House Republicans led by Pete Sessions and Andy Harris — had sent letters urging Trump not to proceed. Freedom Caucus Chair Harris told Marijuana Moment in February: "On this one, they should take about 20 years to grind."
Then came April 18.
Trump signed a separate executive order on psychedelic drugs with Joe Rogan standing directly behind him in the Oval Office. During the signing event, Trump pivoted to cannabis in what appeared to be an impromptu aside. He complained publicly that federal officials were dragging their feet on rescheduling.
"You're going to get the rescheduling done, right, please? Will you get the rescheduling done, please?" Trump said, appearing to address a DOJ or White House official in the room. "You know, they're slow-walking me on rescheduling."
Five days later, the order was signed.
Sources told CNN that the White House and Justice Department had faced intensifying pressure from the cannabis industry. As the plan was being finalized, some officials within DOJ actually hoped to announce it on April 20 — the industry's unofficial holiday — but were told it "would be unseemly." The order was finalized instead for April 22, with the public announcement coming the morning of April 23.
The political context matters enormously. Fortune published an extraordinary analysis on the same day, noting that the psychedelics executive order and the cannabis rescheduling landed during the same week Iran's military had mined the Strait of Hormuz, with a classified Pentagon briefing warning it could take six months to clear the shipping lanes. The timing, Fortune argued, represented cultural wins delivered to "the coalition most central to [Trump's] political survival" — the young male voter bloc that helped swing the 2024 election — while a major geopolitical crisis unfolded largely out of public view.
Whether strategic misdirection or coincidence, the political calculus is clear: cannabis rescheduling costs the administration nothing with its base (polling consistently shows 70%+ support for medical cannabis reform across party lines) while generating enormous goodwill with a constituency that helped deliver the 2024 election. It is, in the language of political operatives, a "free win."
The 280E Earthquake
For cannabis operators, the financial implications dwarf everything else.
Since 1982, Section 280E of the Internal Revenue Code has prohibited businesses trafficking in Schedule I or II substances from deducting ordinary and necessary business expenses on their federal taxes. For the cannabis industry, this has meant effective tax rates of 60-80% — paying federal income tax on gross profit rather than net income — a punitive burden that no other legal industry in America faces.
As of April 22, 2026, that burden is lifted for every state-licensed medical cannabis operator in America.
The order explicitly states that "as a consequence of this rule, state licensees will no longer be subject to the deduction disallowance imposed by Section 280E of the Internal Revenue Code." But the order goes further: Blanche "encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license."
Retrospective relief. Those are two words worth potentially billions of dollars.
The practical implications for tax practitioners are significant. The Current Federal Tax Developments blog published an exhaustive technical analysis within hours of the order, noting that the reclassification "bifurcates the tax treatment of state-legal marijuana businesses" — medical operators are liberated from 280E, while adult-use operators remain fully subject to it. For multi-state operators that hold both medical and recreational licenses, this creates an immediate and complex accounting challenge: segregating deductible medical expenses from non-deductible recreational expenses, potentially across shared facilities, supply chains, and workforces.
The order also opens a new pathway for individual taxpayers. Medical marijuana purchased via a legitimate prescription from a DEA-registered practitioner may now qualify as a deductible medical expense under Section 213 of the Internal Revenue Code — a provision that had been effectively meaningless while cannabis sat in Schedule I.
However, the operative word in the retrospective relief language is "encourages." The order does not mandate Treasury action. It does not constitute a formal determination regarding federal tax liability. And it expressly advises state licensees to consult with tax counsel. Operators would be wise to begin filing amended returns and protective claims for prior tax years immediately, while simultaneously building the cost-segregation systems needed to separate medical and recreational operations going forward. The window for protective claims on the earliest eligible tax years will not stay open indefinitely.
For public company operators, the tax implications are already moving markets. Trulieve, which carried a $668 million uncertain tax liability related to 280E on its most recent balance sheet, saw the potential removal of that overhang as a transformative event. CEO Kim Rivers called the order "the first-ever meaningful policy shift related to cannabis in the history of America." Ascend Wellness CEO Sam Brill, who told NPR before the announcement that his company was paying "a full tax bill on my gross margin, which no other company does except for people in our industry," called it "an important step toward a more transparent and accountable market."
The Market Reaction: Euphoria, Then Reality
Wall Street's response tracked the order's nuance — eventually.
Cannabis stocks surged on Wednesday, April 22, after Axios reported the policy change was imminent. Tilray jumped 14.2%. Canopy Growth climbed 21.1%. Curaleaf soared 26.3%. The MSOS ETF — the largest U.S.-listed cannabis fund — advanced 19.4%.
Then the details landed Thursday morning.
As investors digested the medical-only scope of Phase One, the euphoria evaporated. By Thursday afternoon, Cronos Group, Aurora Cannabis, Canopy Growth, and Tilray had all reversed, slumping 6-10%. The MSOS ETF, which had hit massive trading volume — over 55 million shares — ultimately showed a modest decline on the day. The market's verdict was clear: medical-only rescheduling is meaningful, but it is not the industry-wide transformation that was priced in during Wednesday's rally.
This reaction is instructive. The public companies that dominate cannabis stock indexes are overwhelmingly multi-state operators with significant adult-use exposure. For them, Phase One delivers partial 280E relief at best. The full financial transformation depends on Phase Two — the broader rescheduling hearing that begins June 29 and carries no guarantee of outcome.
AdvisorShares, which manages the MSOS, YOLO, and MSOX ETFs, called the rescheduling "an industry inflection point" while carefully noting it does not instantly solve every structural challenge.
The Prohibitionist Response: Bill Barr Goes to War
The opposition mobilized within hours.
Smart Approaches to Marijuana, the country's preeminent anti-legalization organization, announced it would take "legal action immediately" against the order. SAM retained former U.S. Attorney General William Barr — who served during Trump's first term — as its attorney. Barr's firm, Torridon Law, had previously represented SAM in 2024 when it asked the DEA to extend the public comment period for Biden's rescheduling proposal.
SAM CEO Kevin Sabet issued a blistering statement: "With this move, we are now confronted with the most pro-drug administration in our history. Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction — it is a travesty and injustice to the American people of unprecedented proportions."
In a separate statement to PBS, Sabet argued that "today's marijuana is more dangerous than previously thought, not less dangerous," calling the industry "the new Big Tobacco" and claiming the administration was "welcoming them into the homes of families across this country with open arms."
The legal strategy SAM is likely to pursue is predictable but not without teeth. They will almost certainly seek a temporary restraining order or preliminary injunction to block the order from taking effect while litigation proceeds. The primary attack vectors are procedural: arguing that the 811(d)(1) treaty exception was improperly invoked, that the order's regulatory amendments exceed the AG's authority under that provision, and that bypassing notice-and-comment violated the Administrative Procedure Act.
Whether a court would grant injunctive relief is genuinely uncertain. The 811(d)(1) mechanism has clear statutory grounding and DEA precedent in the Epidiolex scheduling. But the scope of this order — rescheduling an entire category of state-licensed operations, not just a single FDA-approved product — is unprecedented, and judges tend to be cautious about blessing novel exercises of executive authority without giving interested parties an opportunity to be heard.
The severability clause is the DOJ's insurance policy. Even if a court strikes down the regulatory framework portions of the order, the core rescheduling action under the treaty pathway may survive independently.
The GOP Civil War on Cannabis
Senator Tom Cotton wasted no time. "Marijuana today is much more potent than just ten or twenty years ago, leading to increased psychosis, anti-social behavior, and fatal car crashes," he wrote on X. "Arkansans don't want more dangerous drugs obtained more easily. A change to marijuana's drug classification is a step in the wrong direction."
Senator Roger Marshall of Kansas expressed similar disappointment. The 22-senator letter from December — which warned rescheduling would "undermine your strong efforts to Make America Great Again," cited $2.3 billion in industry tax breaks, and warned of benefits flowing to "bad actors such as Communist China" — now reads like a prescient dissent from within the president's own party.
Yet the Republican reaction was notably more restrained than the December letter would have predicted. Reuters described Thursday's GOP response as "more muted," suggesting that with Trump himself driving the action, rank-and-file Republicans may be choosing not to die on this particular hill.
Senator Mike Lee of Utah offered perhaps the most telling reaction of all: "Should've announced it on 4/20."
The Marijuana Policy Project's executive director, Adam J. Smith, called it "a historic move toward sanity in cannabis policy," while progressive Democrats like Jerry Nadler called it "a good first step" that doesn't go far enough. Shri Thanedar was more direct: "Let's be blunt: we need full legalization."
The bipartisan nature of the response — industry-aligned Republicans praising Trump, social-justice Democrats demanding more, prohibitionist Republicans criticizing their own president — illustrates cannabis policy's unique status as an issue that scrambles traditional political alliances.
What the Order Doesn't Do
Precision matters here, because the headlines will get this wrong.
Adult-use cannabis remains Schedule I. If you operate a recreational dispensary in Colorado, California, or any other adult-use state, nothing has changed for you today. Section 280E still applies to your recreational sales. The DEA can still prosecute you under federal law. The only relief available to adult-use operators depends on the outcome of the Phase Two hearing.
Synthetically derived THC remains Schedule I. Delta-8-THC, delta-10-THC, and other synthetically derived cannabinoids created through the hemp loophole in the 2018 Farm Bill are completely unaffected by this order.
Hemp is unaffected. The order does not address hemp as defined under the Agricultural Improvement Act of 2018. The separate hemp regulatory battle — including the November 2025 spending bill provision that effectively bans products containing more than 0.4 milligrams of total THC per container, and the competing HEMP Act from Reps. Griffith and Veasey that would create a federal regulatory framework for hemp-derived products — remains on its own track entirely.
Cannabis is not legalized. Schedule III drugs still require DEA registration, prescriptions from licensed practitioners, production quotas, recordkeeping, and compliance with the full apparatus of federal controlled substances regulation. This is not decriminalization. This is not descheduling. This is reclassification within a heavily regulated framework.
Recreational banking remains uncertain. While some banking barriers may ease for medical operators who achieve DEA registration under the new expedited pathway, the fundamental federal-state conflict for recreational operations remains unresolved.
The International Trade Angle Nobody's Talking About
Here is a detail that most analyses have overlooked: the treaty pathway doesn't just resolve a domestic regulatory problem — it opens the door to international cannabis trade.
The Single Convention requires signatory nations to establish a licensed manufacturing and distribution framework with import-export controls. By explicitly grounding the rescheduling in U.S. treaty obligations, the DOJ has, perhaps inadvertently, created the legal architecture for state-licensed medical cannabis operators to participate in international trade. A DEA-registered manufacturer in Colorado could, in theory, export medical cannabis products to other Single Convention signatories with compatible regulatory frameworks — Canada, Germany, Israel, and others.
Cannabis law firm Harris Sliwoski was among the first to flag this implication, noting that the order means "if you are a foreign medical marijuana operator looking to explore US opportunities, they finally exist (at least for now)." This could eventually prove more transformative than the 280E relief for a segment of the industry.
The Treaty Paradox
There is an exquisite irony embedded in the DOJ's approach.
For decades, the DEA cited U.S. treaty obligations under the Single Convention as a reason cannabis could not be rescheduled below Schedule II. As recently as the Biden administration's treaty analysis, the DEA argued that "several requirements imposed by the Single Convention would not be met if cannabis and cannabis resin were placed in CSA schedule III, IV, or V," citing the D.C. Circuit's 1977 ruling in NORML v. DEA.
Now, the DOJ has used the very same treaty — and the very same statutory provision — as the legal basis for placing cannabis in Schedule III.
The key to squaring this circle is the order's structure. By limiting the immediate rescheduling to products distributed through state medical marijuana programs (which include licensing, regulatory oversight, and patient-access controls) and FDA-approved products (which carry their own regulatory apparatus), the DOJ can argue it has satisfied the Single Convention's requirements for prescriptions, licensed operators, production controls, and recordkeeping — the very requirements the DEA previously argued could not be met under Schedule III.
Whether this argument survives judicial scrutiny is the central legal question of the coming months. The Morningstar analysis was among the most pointed in raising concerns: rescheduling under the treaty pathway "activates U.S. treaty obligations and federal cannabis quotas," meaning DEA oversight of the medical marijuana supply chain becomes not just possible but mandatory. State-licensed operators who celebrate 280E relief today may discover that DEA registration requirements, federal production quotas, and international reporting obligations carry their own compliance burdens.
What Happens Next: Three Scenarios
Scenario 1: The Order Survives, Phase Two Delivers Broad Rescheduling
This is the industry's best case. SAM's legal challenge fails or produces only narrow modifications. The June 29 hearing proceeds on schedule, concludes by July 15, and produces a final rule rescheduling all cannabis to Schedule III by late 2026 or early 2027. Medical operators enjoy immediate 280E relief with retroactive claims. Adult-use operators receive relief within 12-18 months. Banking access improves. Research barriers fall. The cannabis sector begins a multi-year rerating as institutional capital enters the market.
Probability: Moderate. The legal challenge is real, but the treaty pathway has statutory grounding and DEA precedent. The bigger uncertainty is whether the Phase Two hearing's compressed timeline produces a defensible record.
Scenario 2: Partial Victory — Phase One Survives, Phase Two Stalls
A court grants SAM's request for injunctive relief on specific regulatory provisions but leaves the core Schedule III reclassification for medical cannabis intact (thanks to the severability clause). The Phase Two hearing proceeds but produces a contested record. The broader rescheduling gets litigated for years. Medical operators benefit immediately. Adult-use operators remain in 280E purgatory. The industry develops a two-tier structure: federally compliant medical operators with tax relief and DEA registration, and state-legal recreational operators operating in the same gray zone they've inhabited for a decade.
Probability: This may be the most likely outcome. It is also the one the DOJ's bifurcated structure seems designed to accommodate.
Scenario 3: Full Judicial Reversal
A court issues a broad preliminary injunction blocking the entire order on the grounds that 811(d)(1) was improperly invoked for an action of this scope. Rescheduling reverts to the traditional notice-and-comment process, which could take years. The political window closes as Trump's second term enters its final two years and attention shifts to 2028 positioning.
Probability: Low, but not negligible. The 811(d)(1) authority is clear, but the scope of its application here is novel. A hostile judge could find that using a treaty-compliance shortcut to restructure an entire domestic industry exceeds the provision's intent.
The View from Here
This is a genuinely historic moment, and it deserves to be recognized as such without inflating what it is or understating what it isn't.
For the first time since Richard Nixon signed the Controlled Substances Act into law in 1970, the federal government has formally acknowledged what forty state legislatures, hundreds of medical studies, and millions of patients already knew: cannabis has accepted medical use.
The DOJ's approach — fast, surgical, legally creative, and structurally resilient — reflects an administration that wanted to deliver a win without absorbing the political cost of broad legalization. The treaty pathway was the sharpest tool available, and Blanche wielded it with precision.
But the order's limitations are real. Adult-use operators — the economic engine of the modern cannabis industry — got nothing on April 23 except a hearing date. The hemp-derived products market, now worth tens of billions of dollars, was not addressed at all. And the legal challenge from SAM, backed by a former Attorney General who knows exactly how DOJ operates from the inside, represents a credible threat to the order's most ambitious provisions.
The next ninety days will determine whether April 23, 2026, is remembered as the day the federal cannabis prohibition began its irreversible collapse — or as one more step in a reform process that has been marked, for decades, by progress followed by paralysis.
Watch the courts. Watch the June 29 hearing. Watch Treasury for 280E guidance.
And for the first time in the history of this publication, you can watch all of it unfold from Schedule III.